Since 2018 is quickly coming to an end, we look back at the past few months and reflect on all that we have achieved. The launch of the business is all wrapped up and now we look forward to what 2019 will bring. We would like to thank all of our clients and contacts for your support in what has been an incredibly exciting year.
Let’s take a look at our highlights:
We officially launched TherapeutAix in September 2018 after months of preparation. The launch was accompanied by a new website that reflects our brand and our values. Since the website’s launch we have received over 600 visitors and we hope that our presence online will continue to grow along with us.
Our ambition is to help bring molecules with promise to life and we strive to do this by working with our well-established R&D network and using our individual expertise in therapeutic areas.
If you would like to find out more about us, you can do so here.
This year, the TherapeutAix team attended the ERS International Congress in Paris. The team presented a scientific poster with network partner, Nordic BioSciences, that detailed recent activities in developing translational assays and biomarkers to profile potential novel therapeutics for fibrotic lung diseases, including IPF.
The congress was an excellent way for us to network and establish our new brand to fellow scientists. For us, the main takeaway from the meeting was the extent to which availability of treatment options in idiopathic pulmonary fibrosis (IPF) has stimulated interest in fibrosis and anti-fibrotic approaches more broadly, both within and beyond the lung. This evolution we believe raises important considerations for drug discovery and development in the field, a theme we intend to expand upon as we move into 2019.
On the 26th September we attended the Society for Medicines Research (SMR) meeting titled ‘The Best of Both Worlds: Innovation, Collaboration and Synergy between CROs and their Client Partners’ at the GSK Conference Centre in Stevenage. The meeting showcased innovation in science that has emerged from successful Client-CRO partnerships which have moved beyond fee-for-service agreements towards much broader risk-sharing and complementary collaborations.
In attendance were Darcey Black, TherapeutAix’s Translational Director and Bob Humphries, Project Strategy Director. They presented a poster on ‘Advancing Assets in Drug Discovery and Early Development: Building a Platform of Evidence Using Networked R&D’ which included a case study on progressing compounds in idiopathic pulmonary fibrosis.
We were delighted to be involved in the European Laboratory Research & Innovation Group’s (ELRIG) flagship conference regarding Drug Discovery.
The 2-event has become the largest meeting of life sciences industry professionals in the UK and brought together more than 1200 delegates and 100 exhibiting companies.
Bob Humphries & Simon Cruwys presented the ‘Advancing Assets in Drug Discovery and Early Development’ poster. The conference was a roaring success and the perfect opportunity to explore the application of laboratory technology to understand disease biology.
TherapeutAix is pleased to have co-authored a paper with a bit of a twist – aiming to give Discovery Teams some guidance on navigating the maze of information available and some pointers to factors to consider in early research projects.
The full article, The future R&D landscape in non-alcoholic steatohepatitis, is now available online on Drug Discovery today.
Looking ahead to 2019
2018 allowed us to put in place the foundation for TherapeutAix. We now look forward to building on that foundation. Our plans for 2019 include expanding the TherapeutAix team, growing our R&D network and increasing our presence at local and national events. We are also planning a “so what” piece on IPF, suggesting how current treatment trends might influence thinking when progressing new approaches.